All-In Podcast | Dave Ricks, CEO of Eli Lilly | The All-In Interview @allin | Uploaded October 2024 | Updated October 2024, 12 hours ago.
(0:00) Friedberg welcomes Eli Lilly CEO Dave Ricks
(2:06) The obesity problem: a global chronic health epidemic
(13:07) The history of discovering GLP-1s
(20:38) Impact of GLP-1s on different human functions
(27:09) Understanding the commercial aspect of drug discovery, pricing for GLP-1 drugs
(33:11) Responding to criticism and research of GLP-1 dependency
(40:04) Stock performance, dealing with political pressure related to successful drugs
(47:19) Eli Lilly's portfolio of drugs outside of GLP-1s, what science Dave is excited about
(56:09) Scaling and impacting culture at a 100+ year-old company

Follow the besties:
https://x.com/chamath
https://x.com/Jason
https://x.com/DavidSacks
https://x.com/friedberg

Follow on X:
https://x.com/theallinpod

Follow on Instagram:
instagram.com/theallinpod

Follow on TikTok:
tiktok.com/@theallinpod

Follow on LinkedIn:
linkedin.com/company/allinpod

Intro Music Credit:
https://rb.gy/tppkzl
https://x.com/yung_spielburg

Intro Video Credit:
https://x.com/TheZachEffect

Referenced in the show:
google.com/finance/quote/LLY:NYSE
cdc.gov/nchs/data/hestat/obesity-adult-17-18/Estat-adults-fig.png
pbs.org/newshour/politics/fda-approves-new-version-of-diabetes-drug-mounjaro-to-be-sold-for-weight-loss
cnn.com/2024/01/08/health/weight-loss-drug-insurance-denials/index.html
https://i.insider.com/638f471e57aefa0018eb9a3d?width=800&format=jpeg&auto=webp
https://x.com/EconomyApp

#allin #tech #news